The immune system and cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 3, 2009, Pages 369-376

  Loose, David ^a   Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; INTERLEUKIN 10; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTAGLANDIN; PROTEASOME; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN;

ANTIGEN PRESENTATION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL DEATH; CELL DIVISION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MUTANT; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TH2 CELL; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 67650854632     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0593     Document Type: Review

References (82)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer im-munoediting. Annu Rev Immunol 2004;22:329.
2. Moser M, Murphy KM. Dendritic cell regulation of Th1-Th2 development. Nat Immunol 2000;1:199.
3. Gowans JL. The lymphocyte - a disgraceful gap in medical knowledge. Immunol Today 1996;17:288.
4. Atkinson EA, Bleackley RC. Mechanisms of lysis by cytotoxic T-cells. Crit Rev Immunol 1995;15:359.
5. Hishii M, Kurnick JT, Ramirez-Montagut T, et al. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes. Clin Exp Immunol 1999;116:388.
6. Andersen MH, Schrama D, Thor Straten P, et al. Cytotoxic T-cells. J Invest Dermatol 2006;126:32.
7. Benlalam H, Labarriere N, Linard B, et al. Comprehensive analysis of the frequency of recognition of melanomaassociated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): Implications for immunotherapy. Eur J Immunol 2001;31:2007.
8. Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T-cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004;114:67.
9. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T-lymphocytes. J Exp Med 1998;188:1641.
10. Fujiwara H, Fukuzawa M, Yoshioka T, et al. The role of tumor-specific Lyt-1 + 2 - T-cells in eradicating tumor cells in vivo. I. Lyt-1 + 2 - T-cells do not necessarily require recruitment of host's cytotoxic T-cell precursors for implementation of in vivo immunity. J Immunol 1984;133:1671.
11. + cells: Cytolytic T-cells can mediate eradication of disseminated leukemia. J Immunol 1986;136:1917.
12. Mumberg D, Monach PA, Wanderling S, et al. CD4(+) T-cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 1999; 96:8633.
13. Beatty GL, Paterson Y. IFN-gamma can promote tumor evasion of the immune system in vivo by downregulating cellular levels of an endogenous tumor antigen. J Immunol 2000;165:5502.
14. Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230:221.
15. Karre K. Express yourself or die: Peptides, MHC molecules, and NK cells. Science 1995;267:978.
16. Yokoyama WM. Natural killer cell receptors. Curr Opin Immunol 1998;10:298.
17. Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific T-cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002;3:83.
18. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327.
19. Caligiuri MA, Zmuidzinas A, Manley TJ, et al. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509.
20. Basse P, Herberman RB, Nannmark U, et al. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 1991;174:479.
21. Lister J, Rybka WB, Donnenberg AD, et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1995;1:607.
22. Nagashima S, Reichert TE, Kashii Y, et al. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2. Cancer Gene Ther 1997;4:366.
23. Lopez CB, Rao TD, Feiner H, et al. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol 1998;190:141.
24. Agarwal A, Rani M, Saha GK, et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003;32:17.
25. Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772.
26. Buelens C, Verhasselt V, De Groote D, et al. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage colony-stimulating factor. Eur J Immunol 1997;27:756.
27. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28: 359.
28. Constam DB, Philipp J, Malipiero UV, et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992;148:1404.
29. Fontana A, Constam DB, Frei K, et al. Modulation of the immune response by transforming growth factor-beta. Int Arch Allergy Immunol 1992;99:1.
30. Moustakas A, Pardali K, Gaal A, et al. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 2002;82:85.
31. Yeudall WA, Miyazaki H. Chemokines and squamous cancer of the head and neck: Targets for therapeutic intervention? Expert Rev Anticancer Ther 2007;7:351.
32. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) pro- genitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778.
33. Chomarat P, Banchereau J, Davoust J, et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1:510.
34. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004;173:3844.
35. + natural suppressor cells. Int J Cancer 1997;74:69.
36. Herberman RB, Holden HT, Djeu JY, et al. Macrophages as regulators of immune responses against tumors. Adv Exp Med Biol 1979;121B:361.
37. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362.
38. Lang S, Tiwari S, Andratschke M, et al. Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. Cancer Immunol Immunother 2007;56:1645.
39. Tang N, Wang L, Esko J, et al. Loss of HIF-1-alpha in en-dothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485.
40. Takahashi A, Kono K, Ichihara F, et al. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cyto-kines. Cancer Immunol Immunother 2004;53:543.
41. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bev-acizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502.
42. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carbo-platin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184.
43. Redondo M, Garcia J, Villar E, et al. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003;34:1283.
44. Ruiz-Cabello F, Perez-Ayala M, Gomez O, et al. Molecular analysis of MHC class I alterations in human tumor cell lines. Int J Cancer Suppl 1991;6:123.
45. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T-cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340.
46. Yamshchikov GV, Mullins DW, Chang CC, et al. Sequential immune escape and shifting of T-cell responses in a long-term survivor of melanoma. J Immunol 2005;174:6863.
47. Lotteau V, Teyton L, Peleraux A, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;348:600.
48. Busch R, Cloutier I, Sekaly RP, et al. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996;15:418.
49. Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompati-bility complex class II folding, transport, and peptide occupancy. J Exp Med 1994;180:1107.
50. Germain RN. MHC-Dependent antigen processing and peptide presentation: providing ligands for T-lymphocyte activation. Cell 1994;76:287.
51. Fremont DH, Crawford F, Marrack P, et al. Crystal structure of mouse H2-M. Immunity 1998;9:385.
52. Kropshofer H, Vogt AB, Moldenhauer G, et al. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996;15: 6144.
53. Roberts RA, Wright G, Rosenwald AR, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006;108:311.
54. Matoba K, Iizuka N, Gondo T, et al. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepato-cellular carcinoma. Int J Cancer 2005;115:231.
55. Chamuleau ME, Souwer Y, Van Ham SM, et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004;64:5546.
56. Tamori Y, Tan X, Nakagawa K, et al. Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. Oncol Rep 2005;14:873.
57. Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol 1996;8:59.
58. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259.
59. Macagno A, Gilliet M, Sallusto F, et al. Dendritic cells upregulate immunoproteasomes and the proteasome regulator, PA28, during maturation. Eur J Immunol 1999;29: 4037.
60. van Hall T, Sijts A, Camps M, et al. Differential influence on cytotoxic T-lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J Exp Med 2000;192:483.
61. Schwarz K, van Den Broek M, Kostka S, et al. Over-expression of the proteasome subunits, LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T-cell epitope. J Immunol 2000;165:768.
62. Sijts AJ, Standera S, Toes RE, et al. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J Immunol 2000;164:4500.
63. Morel S, Levy F, Burlet-Schiltz O, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000;12:107.
64. Van den Eynde BJ, Morel S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 2001;13:147.
65. Lenardo MJ. Interleukin-2 programs mouse alpha beta T-lymphocytes for apoptosis. Nature 1991;353:858.
66. Van Parijs L, Refaeli Y, Lord JD, et al. Uncoupling IL-2 signals that regulate T-cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 1999;11:281.
67. Green DR, Bissonnette RP, Glynn JM, et al. Activationinduced apoptosis in lymphoid systems. Semin Immunol 1992;4:379.
68. Saff RR, Spanjaard ES, Hohlbaum AM, et al. Activationinduced cell death limits effector function of CD4 tumorspecific T-cells. J Immunol 2004;172:6598.
69. Bennett MW, O'Connell J, O'Sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160: 5669.
70. Okada K, Komuta K, Hashimoto S, et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000;6:3560.
71. Reichert TE, Strauss L, Wagner EM, et al. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137.
72. Yagita H, Seino K, Kayagaki N, et al. CD95 ligand in graft rejection. Nature 1996;379:682.
73. Zietz C, Rumpler U, Sturzl M, et al. Inverse relation of Fasligand and tumor-infiltrating lymphocytes in angiosarcoma: Indications of apoptotic tumor counterattack. Am J Pathol 2001;159:963.
74. Mann B, Gratchev A, Bohm C, et al. Fas-L is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999;79:1262.
75. Yoong KF, Afford SC, Randhawa S, et al. Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999;154:693.
76. Younes M, Schwartz MR, Ertan A, et al. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 2000;88:524.
77. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357:539.
78. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:938.
79. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793.
80. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089.
81. Kim JW, Wieckowski E, Taylor DD, et al. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T-lymphocytes. Clin Cancer Res 2005;11:1010.
82. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303.